June 11, 2021 -- Vor Biopharma has entered into a multiyear strategic collaboration and license agreement with Abound Bio to research both single- and multitargeted chimeric antigen receptor (CAR) T-cell treatments.
Under the terms of the agreement, the CAR T treatments will be used in combination with Vor's engineered hematopoietic stem cell platform, which shields the patient from unwanted side effects. The goal is to generate novel treatment systems for patients with acute myeloid leukemia and other forms of blood cancer, the companies said.
Financial terms of the deal were not disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
